SHANGHAI – Glaxosmithkline plc sent three top global executives to China to deal with an expanding scandal that has seen four executives detained and one confess on national television.
SHANGHAI – Glaxosmithkline plc sent three top global executives to China to deal with an expanding scandal that has seen four executives detained and one confess on national television.
SHANGHAI – Officials in China said a number of executives at Glaxosmithkline plc (GSK) are now officially under investigation "for suspicions of serious economic crimes" that potentially involve deals worth ¥3 billion (US$488 million).
SHANGHAI – Officials in China said a number of executives at Glaxosmithkline plc (GSK) are now officially under investigation "for suspicions of serious economic crimes" that potentially involve deals worth ¥3 billion (US$488 million).
SHANGHAI – The Chinese Ministry of Health has published the Good Supply Practice (GSP) Standards for Pharmaceutical Products in part in an effort to continue the consolidation of the Chinese drug distribution industry by eliminating smaller and less efficient distributors.
SHANGHAI – Looking to create synergies between its own expertise and growing pool of small and medium biotech ventures in China, Boehringer Ingelheim Pharmaceuticals GmbH (BI) plans to build the first international biopharma contract manufacturing facility (CMO) in the country with mammalian cell technology.
SHANGHAI – Looking to create synergies between its own expertise and growing pool of small and medium biotech ventures in China, Boehringer Ingelheim Pharmaceuticals GmbH (BI) plans to build the first international biopharma contract manufacturing facility (CMO) in the country with mammalian cell technology.
SHANGHAI, China – Chinese biopharmaceutical companies are unlikely to benefit much from a relaxation in an 8-month-old ban on new initial public offerings (IPOs) or from new draft regulations aimed at improving disclosures and governance.
SHANGHAI, China – In its first China deal, San Diego-based biopharma developer Ambrx Inc. will work with Zhejiang Medicine Co. (ZMC) to develop a new breast cancer drug.
